SEC Form 4 · accession 0000899243-18-017781

Eidos Therapeutics, Inc. · EIDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 22, 2018

Accepted (ET)

Jun 22, 2018 · 7:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001731831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Jun 22, 2018	C	1,103,847	—	A	1,103,847	I	See footnote
Common Stock^F4,F5,F3	Jun 22, 2018	P	1,058,824	$17.00	A	2,162,671	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Convertible Preferred Stock^F6,F3,F1	—	Jun 22, 2018	C	922,950	D	—	—	Common Stock	1,103,847	0	I

F1The convertible preferred stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a 1.196-for-one basis, and had no expiration date.
F2Includes (a) 898,533 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P.(the "Fund") and (b) 205,314 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
F3RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a member of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.
F4Includes (a) 856,266 shares of Common Stock held by the Fund and (b) 202,558 held in the Account, in each case acquired in the Issuer's initial public offering.
F5These securities include 1,754,799 shares held by the Fund and 407,872 shares held in the Account.
F6Represents 751,282 shares of Series B Convertible Preferred Stock held by the Fund and 171,668 shares of Series B Convertible Preferred Stock held in the Account.